TY  - JOUR
AU  - Lopez-Beltran, Antonio
AU  - Cimadamore, Alessia
AU  - Blanca, Ana
AU  - Massari, Francesco
AU  - Vau, Nuno
AU  - Scarpelli, Marina
AU  - Cheng, Liang
AU  - Montironi, Rodolfo
PY  - 2020
DO  - 10.3390/cancers13010131
SN  - 2072-6694
UR  - http://hdl.handle.net/10668/16926
T2  - Cancers
AB  - A number of immune checkpoint inhibitors (ICIs) have been approved as first-line therapy in case of cisplatin-ineligible patients or as second-line therapy for patients with metastatic urothelial carcinoma (mUC) of the bladder. About 30% of patients...
LA  - en
PB  - MDPI
KW  - Atezolizumab
KW  - Avelumab
KW  - Durvalumab
KW  - Nivolumab
KW  - PD-1
KW  - PD-L1
KW  - Pembrolizumab
KW  - Biomarker
KW  - Bladder cancer
KW  - Immune checkpoint inhibitor
KW  - Immunotherapy
KW  - Tumor mutation burden
KW  - Urothelium
KW  - Variant histology
TI  - Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer.
TY  - research article
VL  - 13
ER  -